Boehringer Ingelheim Articles
Dabigatran as effective in VTE as enoxaparin
24 September 2007
Boeh Ing and Ablynx sign development deal
17 September 2007
Boeh Ing to start Ph III BIBW 2992 study
17 September 2007
Depression prevalent in PD, says study
10 September 2007
Competition in the venous thromboembolism market
20 August 2007
Evotec revenues dip
20 August 2007
Laureate's 2nd-qtr revenue surges 178%
13 August 2007
Boeh Ing's Viramune may cut CV risk
6 August 2007
Boeh Ing's 1st half 2007 sales up 2.1%
6 August 2007
Strong female-specific data for Aptivus
6 August 2007
Spiriva Respimat OKed for COPD in Europe
30 July 2007
Galapagos unit gets payment from Boeh Ing
30 July 2007
InterMune/Boeh Ing agree Actimmune supply accord
26 July 2007
Barr challenges Boeh Ing's Aggrenox patent
23 July 2007
Boeh Ing's dabigatran as effective as enoxaparin
16 July 2007
Ark granted key European stroke patent
16 July 2007
Boeh Ing initiates Ph IIIb Aptivus study
25 June 2007
Pramipexole: broad effectiveness in RLS
18 June 2007
Bayer to showcase health care business to analysts
18 June 2007
Boeh Ingelheim amends Viramune license
4 June 2007
Bulgarian pharma market grows 18.5%
4 June 2007
Less pain for depressives switched to duloxetine
4 June 2007
Vectura's fiscal 2006 revenues increase 67%
4 June 2007
Evotec swings to 1st-qtr 2007 profit
21 May 2007
BI starts enrollment in ArTEN HIV trial
21 May 2007
Boeh Ing's Actilyse gets nod from NICE
21 May 2007
Laureate sees momentum continue
7 May 2007
Boeh Ingelheim sales leap 17.3% in Japan
23 April 2007
Surprise rise in German drug investment
23 April 2007
Evotec's reports mixed performance in 2006
9 April 2007
Bentley's Spanish units get approval for tamulosin
2 April 2007
Evotec and BI in Alzheimer's discovery collaboration
26 March 2007
Boehringer Ingelheim's duloxetine addresses emotional symptoms and pain in depression trial
26 March 2007
Ark Thera's 2006 loss up 16%, on R&D costs
19 March 2007
13 new drugs added to Japan's NHI list
19 March 2007
Japan stock market week to March 5, 2007
12 March 2007
Aptivus resistant HIV still responds to darunavir
12 March 2007
MNCs in Serbia move for "transparency"
12 March 2007
US FDA approves Lilly's Cymbalta in GAD
5 March 2007
Boehringer cancels deal with IdeaSphere
26 February 2007
Xencor enters Ab optimization deal with Boeh Ingel
19 February 2007
Boeh Ingel posts strong long-term data on Viramune
5 February 2007
Abbott suffers 4th-qtr $0.37 LPS on Kos buy
5 February 2007
Boehringer targets 2009 US appro for flibanserin in HSDD
15 January 2007
Idenix recruits Douglas Mayers as exec VP and CMO
15 January 2007
Boeh Ingel enters $265M Nanobody R&D deal
15 January 2007
World's "10 most promising" treatments
15 January 2007
Oral dabigetran as effective as enoxaparin
18 December 2006
Biota signs $102M HCV accord with Boeh Ing
4 December 2006
Vectura buys Innovata in L129M share deal
27 November 2006
Promising long-term data for Boehringer's Aptivus
20 November 2006
MorphoSys expands Boeh Ing R&D accord
20 November 2006
Strong data for BI's pramipexole in broad range of RLS patients, even those with concomitant diseases
6 November 2006
Boeh Ing buys J&J/Pfizer's OTC Zantac
23 October 2006
EASD panels recommend insulin acceptance, and highlight shortfalls in DPNP therapy
25 September 2006
Doctors complain of poor training in depression diagnosis
25 September 2006
Bayer/J&J and BI atrial fibrillation drugs "have blockbuster potential"
18 September 2006
Appointments and promotions at Watson Pharma
11 September 2006
BI/Pfizer's Spiriva improves lung function in mild COPD
11 September 2006
Boeh Ing reports strong mood data for RLS drug
11 September 2006
Boeh Ing sells Pharmaton business to IdeaSphere
4 September 2006
CORRECTION: IAS HIV treatment guidelines
4 September 2006
Boeh Ing terminates Ph III Metalyse study
31 July 2006
FDA approves first generic meloxicam
24 July 2006
Japan stock market week to July 10, 2006
17 July 2006
Nippon BI seeks new indication for Micardis
17 July 2006
BI's Aptivus linked to intracranial bleeding
10 July 2006
BI's Micardis lowers BP more than other ARBs
26 June 2006
Vectura's year-to-March 2006 income soars 88%
5 June 2006
DDW study reveals large market for BI's Bucospan
29 May 2006
Altana in talks to sell pharma unit
8 May 2006
FivePrime signs $75M RA Boeh Ing accord
1 May 2006
Record growth for Boeh Ing Japan
1 May 2006
Ventura and Boeh Ing sign R&D deal
24 April 2006
Stock Commentary - Europe - week to April 10, 2006
17 April 2006
Spanish pharma goes to court for hospital debts
17 April 2006
COPD market set to grow 9% a year to reach $12B by 2014
17 April 2006
Boehringer Ingelheim: strong data for pramipexole in RLS
10 April 2006
Boeh Ingelheim 2005 sales grow 17%
10 April 2006
Dieter Hinzen nominated to Schering AG supervisory board
20 March 2006
Parexel's TGN 1412 drug trial suspended
20 March 2006
Evotec gets 2nd milestone from Boeh Ing
20 March 2006
Japan's pharma licks its wounds after NHI cuts
13 March 2006
Inspire licenses Boeh Ing's epistatine
27 February 2006
Eli Lilly and BI alter Yentreve/AriClaim deal
20 February 2006
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
